Workflow
Sunshine Guojian Pharmaceutical(688336)
icon
Search documents
三生国健(688336) - 三生国健:第五届董事会第十二次会议决议公告
2025-09-26 10:30
证券代码:688336 证券简称:三生国健 公告编号:2025-057 三生国健药业(上海)股份有限公司 第五届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 三生国健药业(上海)股份有限公司(以下简称"公司")第五 届董事会第十二次会议于 2025 年 9 月 26 日以通讯和现场结合方式召 开。本次会议应出席董事 7 人,实际出席会议董事 7 人。会议由董事 长 LOU JING 先生召集和主持。会议的召集和召开程序,符合《中华 人民共和国公司法》和《三生国健药业(上海)股份有限公司章程》 (以下简称"《公司章程》")的有关规定。 二、董事会会议审议情况 (一)审议通过《关于 2024 年限制性股票激励计划首次授予部 分第一个归属期符合归属条件的议案》 根据《上市公司股权激励管理办法》《激励计划(草案)》《三 生国健药业(上海)股份有限公司 2024 年限制性股票激励计划实施 考核管理办法》、公司《2024 年年度审计报告》及激励对象个人绩 效考核结果,本次激励计划首 ...
三生国健:9月26日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-09-26 10:21
截至发稿,三生国健市值为345亿元。 (记者 曾健辉) 每经AI快讯,三生国健(SH 688336,收盘价:55.97元)9月26日晚间发布公告称,公司第五届第十二 次董事会会议于2025年9月26日以通讯和现场结合方式召开。会议审议了《关于作废部分已授予尚未归 属的2024年限制性股票的议案》等文件。 每经头条(nbdtoutiao)——5年增长33倍,这类新险种卖爆了,身边很多人都需要,30多家险企蜂拥而 入⋯⋯ 2024年1至12月份,三生国健的营业收入构成为:医药制造占比83.02%,CDMO业务占比10.19%,授权 许可占比5.54%,其他业务占比1.25%。 ...
生物制品板块9月25日跌0.21%,诺思兰德领跌,主力资金净流出2.07亿元
Market Overview - The biopharmaceutical sector experienced a decline of 0.21% on September 25, with Nossland leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aopu Mai (688293) with a closing price of 62.85, up 7.42% and a trading volume of 30,600 [1] - Rongchang Biotech (688331) closed at 108.50, up 3.43% with a trading volume of 89,200 [1] - Baipusais (301080) closed at 62.16, up 3.43% with a trading volume of 43,500 [1] - Major decliners included: - Nossland (430047) closed at 22.99, down 3.69% with a trading volume of 57,000 [2] - Wufan Biotech (301393) closed at 53.12, down 3.42% with a trading volume of 24,600 [2] - Kexing Pharmaceutical (688136) closed at 38.75, down 3.34% with a trading volume of 53,500 [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 207 million yuan from institutional investors, while retail investors contributed a net inflow of 45.07 million yuan [2] - Notable capital flows included: - Rongchang Biotech (688331) with a net inflow of 1.021 billion yuan from institutional investors [3] - Junshi Biosciences (688180) with a net inflow of 35.36 million yuan from institutional investors [3] - Aopu Mai (688293) with a net inflow of 9.41 million yuan from institutional investors [3]
生物制品板块9月24日涨0.09%,甘李药业领涨,主力资金净流入8635.78万元
Market Overview - On September 24, the biopharmaceutical sector rose by 0.09% compared to the previous trading day, with Ganli Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3853.64, up 0.83%, while the Shenzhen Component Index closed at 13356.14, up 1.8% [1] Individual Stock Performance - Ganli Pharmaceutical (603087) closed at 79.34, with a significant increase of 10.00% and a trading volume of 343,300 shares, resulting in a transaction value of 2.696 billion yuan [1] - Other notable performers included: - Sanofi (688336) at 55.98, up 5.11% with a transaction value of 431 million yuan [1] - Aidi Pharmaceutical (688488) at 15.26, up 4.88% with a transaction value of 174 million yuan [1] - Nuoviz (688105) at 22.65, up 4.47% with a transaction value of 91.03 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector saw a net inflow of 86.36 million yuan from institutional investors, while retail investors experienced a net outflow of 69.34 million yuan [2] - The capital flow for individual stocks showed that Ganli Pharmaceutical had a net inflow of 14.4 million yuan from institutional investors, but a net outflow of 85.14 million yuan from retail investors [3] - Changchun High-tech (000661) had a net inflow of 43.56 million yuan from institutional investors, while retail investors faced a net outflow of 88.37 million yuan [3]
三生国健股价涨5.13%,泰信基金旗下1只基金重仓,持有21.48万股浮盈赚取58.65万元
Xin Lang Cai Jing· 2025-09-24 05:25
Company Overview - Sanofi Guojian Pharmaceutical Co., Ltd. is located in the China (Shanghai) Free Trade Zone and was established on January 25, 2002. The company went public on July 22, 2020. Its main business involves the research, production, and sales of antibody drugs [1] - The revenue composition of the company includes 75.24% from product sales, 15.37% from commissioned processing services, 7.94% from licensing services, and 1.44% from leasing services [1] Stock Performance - On September 24, the stock price of Sanofi Guojian increased by 5.13%, reaching 55.99 CNY per share, with a trading volume of 273 million CNY and a turnover rate of 0.81%. The total market capitalization is 34.534 billion CNY [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Taixin Fund has a significant position in Sanofi Guojian. The Taixin Medical Service Mixed Initiation A Fund (013072) held 214,800 shares in the second quarter, accounting for 5.15% of the fund's net value, making it the sixth-largest holding [2] - The Taixin Medical Service Mixed Initiation A Fund was established on December 29, 2021, with a latest scale of 31.5558 million CNY. Year-to-date returns are 40.41%, ranking 1725 out of 8173 in its category, while the one-year return is 75.06%, ranking 1478 out of 7996 [2] Fund Manager Information - The fund manager of Taixin Medical Service Mixed Initiation A Fund is Chen Ying, who has been in the position for 3 years and 252 days. The total asset size of the fund is 564 million CNY, with the best return during the tenure being 37.02% and the worst return being -5.65% [3]
三生国健(688336):出海BD迎来突破性进展,临床后期候选药物进展迅速
Huachuang Securities· 2025-09-18 04:42
Investment Rating - The report maintains a "Recommended" rating for the company, indicating an expectation to outperform the benchmark index by 10%-20% over the next six months [22]. Core Insights - The company reported a revenue of 642 million yuan for the first half of 2025, representing a year-on-year increase of 7.61%. The net profit attributable to shareholders was 190 million yuan, up 46.96%, primarily due to steady sales growth and a decrease in sales expenses compared to the same period last year [1]. - The company has made significant progress in its clinical pipeline, with multiple late-stage candidates advancing rapidly. Notably, the company has achieved a breakthrough in international business development (BD) with Pfizer, securing a record upfront payment of 1.25 billion USD for the exclusive development and commercialization rights of a dual antibody product [6][1]. - The company is actively developing differentiated early-stage pipelines, with innovative targets leading in domestic progress. The first approved IND for BDCA2 monoclonal antibody is currently in Phase I clinical trials for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) [6]. Financial Summary - The projected total revenue for 2025 is estimated at 4.199 billion yuan, reflecting a year-on-year growth of 251.8%. The net profit attributable to shareholders is expected to reach 2.775 billion yuan, with a growth rate of 293.9% [1][7]. - The earnings per share (EPS) for 2025 is projected to be 4.50 yuan, with a price-to-earnings (P/E) ratio of 12 [1][7]. - The company's total market capitalization is approximately 32.943 billion yuan, with a debt-to-equity ratio of 5.80% [3].
三生国健跌2.01%,成交额1.08亿元,主力资金净流出614.42万元
Xin Lang Cai Jing· 2025-09-16 03:07
Company Overview - Sanofi Guojian is primarily engaged in the research, production, and sales of antibody drugs, with its main business revenue composition being 75.24% from product sales, 15.37% from commissioned processing services, 7.94% from licensing services, and 1.44% from leasing services [1] - The company was established on January 25, 2002, and was listed on July 22, 2020 [1] Financial Performance - For the first half of 2025, Sanofi Guojian achieved operating revenue of 642 million yuan, representing a year-on-year growth of 7.61%, and a net profit attributable to shareholders of 190 million yuan, which is a year-on-year increase of 46.96% [2] - Since its A-share listing, the company has distributed a total of 107 million yuan in dividends [3] Stock Market Activity - As of September 16, the stock price of Sanofi Guojian was 53.61 yuan per share, with a market capitalization of 33.066 billion yuan [1] - The stock has seen a year-to-date increase of 151.34%, but has experienced a decline of 4.05% over the last five trading days [1] - The company has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on May 27, where it recorded a net purchase of 657,000 yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders of Sanofi Guojian was 12,800, an increase of 19.01% from the previous period, with an average of 48,028 circulating shares per person, a decrease of 15.97% [2] - Notable new institutional shareholders include ICBC Frontier Medical Stock A and China Europe Medical Health Mixed A, holding 3.199 million shares and 3.055 million shares respectively [3]
三生国健(688336) - 国浩律师(上海)事务所关于三生国健药业(上海)股份有限公司2025年第五次临时股东大会的法律意见书
2025-09-15 11:15
国浩律师(上海)事务所 法律意见书 国浩律师(上海)事务所 关于三生国健药业(上海)股份有限公司 2025 年第五次临时股东大会的 法律意见书 致:三生国健药业(上海)股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民 共和国证券法》(以下简称"《证券法》")和中国证券监督管理委员会《上市 公司股东会规则》(以下简称"《股东会规则》")的规定,国浩律师(上海) 事务所接受三生国健药业(上海)股份有限公司(以下简称"公司")董事会的 聘请,指派律师现场见证了公司于 2025年9月 15 目 10:00 起在中国(上海)自由 贸易试验区李冰路 399 号公司会议室召开的公司 2025年第五次临时股东大会,并 依据有关法律、法规、规范性文件的规定以及《三生国健药业〈上海)股份有限 公司章程》(以下简称"《公司章程》")的规定,对本次股东大会的召集、召 开程序、出席人员资格、大会表决程序等事宜进行了审查,现发表法律意见如下: 一、股东大会的召集、召开程序 公司董事会已于 2025 年 8 月 30 日在中国证监会指定信息披露网站上向公司 股东发出了召开 2025 年第五次临时股东大会的会 ...
三生国健(688336) - 三生国健:2025年第五次临时股东大会决议公告
2025-09-15 11:15
证券代码:688336 证券简称:三生国健 公告编号:2025-054 三生国健药业(上海)股份有限公司 2025年第五次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 会议召开和出席情况 (一) 股东大会召开的时间:2025 年 9 月 15 日 (二) 股东大会召开的地点:中国(上海)自由贸易试验区李冰 路 399 号公司会议室 (三) 出席会议的普通股股东、特别表决权股东、恢复表决权的 优先股股东及其持有表决权数量的情况: | 1、出席会议的股东和代理人人数 | 121 | | --- | --- | | 普通股股东人数 | 121 | | 2、出席会议的股东所持有的表决权数量 | 530,461,393 | | 普通股股东所持有表决权数量 | 530,461,393 | | 3、出席会议的股东所持有表决权数量占公司表决权 | 86.0041 | | --- | --- | | 数量的比例(%) | | | 普通股股东所持有表决权数量占公司表决权数量的 | 86.0041 | | 比例(%) ...
三生国健(688336) - 三生国健:2025年第五次临时股东大会会议资料
2025-09-10 09:45
证券代码:688336 证券简称:三生国健 三生国健药业(上海)股份有限公司 2025 年第五次临时股东大会会议资料 二〇二五年九月 1 目录 | 2025 | 年第五次临时股东大会会议须知 | 3 | | --- | --- | --- | | 2025 | 年第五次临时股东大会会议议程 | 6 | | 2025 | 年第五次临时股东大会会议议案 | 9 | | 议案 | 1、《关于公司<2025 年中期利润分配方案>的议案》 | 9 | | 议案 | 2、《关于取消监事会、废止<监事会议事规则>并修订<公司章程>的议案》 | ... 10 | | 议案 | 3、《关于修订和制定部分公司治理制度的议案》 | 11 | | 议案 | 4、《关于选举第五届董事会独立董事的议案》 | 13 | 2 三生国健药业(上海)股份有限公司 2025 年第五次临时股东大会会议须知 为了维护全体股东的合法权益,确保股东大会的正常秩序和议事 效率,保证大会的顺利进行,根据《中华人民共和国公司法》《中华 人民共和国证券法》《上市公司股东会规则》以及《三生国健药业(上 海)股份有限公司章程》(以下简称"《公司章程》")、《三生国 ...